BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 26203926)

  • 1. Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging.
    Møller S; Lundemann M; Law I; Poulsen HS; Larsson HB; Engelholm SA
    Acta Oncol; 2015; 54(9):1521-8. PubMed ID: 26203926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature.
    Jia ZZ; Shi W; Shi JL; Shen DD; Gu HM; Zhou XJ
    Eur J Radiol; 2017 Feb; 87():120-124. PubMed ID: 28034567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
    Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
    J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.
    Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V
    Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.
    Müller A; Jurcoane A; Kebir S; Ditter P; Schrader F; Herrlinger U; Tzaridis T; Mädler B; Schild HH; Glas M; Hattingen E
    Cancer Med; 2017 Jan; 6(1):89-99. PubMed ID: 27891815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.
    Piludu F; Marzi S; Pace A; Villani V; Fabi A; Carapella CM; Terrenato I; Antenucci A; Vidiri A
    Neuroradiology; 2015 Dec; 57(12):1269-80. PubMed ID: 26364181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
    Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
    Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamic susceptibility contrast-enhanced perfusion magnetic resonance (MR) imaging combined with contrast-enhanced MR imaging in the follow-up of immunogene-treated glioblastoma multiforme.
    Stenberg L; Englund E; Wirestam R; Siesjö P; Salford LG; Larsson EM
    Acta Radiol; 2006 Oct; 47(8):852-61. PubMed ID: 17050367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.
    Puig J; Blasco G; Daunis-I-Estadella J; Alberich-Bayarri A; Essig M; Jain R; Remollo S; Hernández D; Puigdemont M; Sánchez-González J; Mateu G; Wintermark M; Pedraza S
    Neuroradiology; 2016 Jan; 58(1):17-26. PubMed ID: 26438560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Difference in the intratumoral distributions of extracellular-fluid and intravascular MR contrast agents in glioblastoma growth.
    Kim JH; Suh JY; Woo DC; Sung YS; Son WC; Choi YS; Pae SJ; Kim JK
    NMR Biomed; 2016 Dec; 29(12):1688-1699. PubMed ID: 27723161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
    Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
    Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.
    Artzi M; Liberman G; Nadav G; Blumenthal DT; Bokstein F; Aizenstein O; Ben Bashat D
    J Neurooncol; 2016 May; 127(3):515-24. PubMed ID: 26754857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pseudoprogression in patients with glioblastoma: added value of arterial spin labeling to dynamic susceptibility contrast perfusion MR imaging.
    Choi YJ; Kim HS; Jahng GH; Kim SJ; Suh DC
    Acta Radiol; 2013 May; 54(4):448-54. PubMed ID: 23592805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MR Perfusion-derived Hemodynamic Parametric Response Mapping of Bevacizumab Efficacy in Recurrent Glioblastoma.
    Kickingereder P; Radbruch A; Burth S; Wick A; Heiland S; Schlemmer HP; Wick W; Bendszus M; Bonekamp D
    Radiology; 2016 May; 279(2):542-52. PubMed ID: 26579564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models.
    Kickingereder P; Burth S; Wick A; Götz M; Eidel O; Schlemmer HP; Maier-Hein KH; Wick W; Bendszus M; Radbruch A; Bonekamp D
    Radiology; 2016 Sep; 280(3):880-9. PubMed ID: 27326665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
    Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
    PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perfusion and diffusion MRI of glioblastoma progression in a four-year prospective temozolomide clinical trial.
    Leimgruber A; Ostermann S; Yeon EJ; Buff E; Maeder PP; Stupp R; Meuli RA
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):869-75. PubMed ID: 16226399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
    Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
    J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative evaluation of dynamic contrast-enhanced perfusion with diffusion tensor imaging metrics in assessment of corticospinal tract infiltration in malignant glioma.
    Awasthi R; Verma SK; Haris M; Singh A; Behari S; Jaiswal AK; Rajput D; Pandey R; Rathore RK; Pandey CM; Gupta RK
    J Comput Assist Tomogr; 2010 Jan; 34(1):82-8. PubMed ID: 20118727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.